摘要
目的对比观察普罗帕酮、胺碘酮、美托洛尔治疗阵发性心房颤动(PAF)的疗效和安全性。方法对80例阵发性心房颤动患者随机分组使用普罗帕酮(32例)、胺碘酮(28例)、美托洛尔(20例)治疗。结果三组患者服药后48小时内有效率分别为72%、75%、65%,组间比较均无统计学意义(P>0.05);不同年龄组之间的有效率均无统计学意义(P>0.05)。三组药物的不良反应发生率分别为16%、14%、15%,均无统计学意义(P>0.05);未见严重毒副反应及致心律失常作用。结论三种药物治疗PAF均有较好疗效,且相对安全。
Objective To investigate the efficacy and safety of propafenone,admiodarane,metoprolol and tartrate capsules（Betaloc） in treating and preventing of paroxysmal atrial fibrillation（PAF）.Methods 80 patients with atrial fibrillation were randomly divided into propafenone（n=32）,admiodarane（n=28） and metoprolol group（n=20）.Results The recovery rates within 48 hours after treatment in propafenone,admiodarane and metoprolol group were 72%,75% and 65% respectively.No significant difference was found in three groups（P〉0.05）.There was no significant difference among different age groups（P〉0.05）.The occurrence rates of adverse reactions in the propafenone,admiodarane and metoprolol group were 16%,14% and 15% respectively.There was no significant difference（P〉0.05）.No serious side effect or arrhythmia was found.Conclusion Three drugs are effective and relatively safe in the treatment and prevention of the relapse of PAF.
出处
《东南国防医药》
2010年第3期232-234,共3页
Military Medical Journal of Southeast China
关键词
心房颤动
普罗帕酮
胺碘酮
美托洛尔
atrial fibrillation
propafenone
admiodarane
metoprolol
